Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

Abstract

Background Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase inhibitor. In an exploratory study, the combination of tucidinostat with exemestane showed preliminary signs of encouraging anti-tumour activity in patients with advanced hormone receptor-positive breast cancer. To build on these findings, we aimed to assess the efficacy and safety of this combination in a randomised trial in a larger population of postmenopausal patients with advanced, hormone receptor-positive breast cancer. Methods We did the randomised, double-blind, placebo-controlled, phase 3 ACE trial at 22 specialist cancer centres in China. Eligible patients were postmenopausal women (aged ≥60 years or aged Findings Between July 20, 2015, and June 26, 2017, 365 patients were enrolled and randomly assigned, 244 to the tucidinostat group and 121 to the placebo group. The median duration of follow-up was 13·9 months (IQR 9·8-17·5). Investigator-assessed median progression-free survival was 7·4 months (95% CI 5·5-9·2) in the tucidinostat group and 3·8 months (3·7-5·5) in the placebo group (HR 0·75 [95% CI 0·58-0·98]; p=0·033). The most common grade 3 or 4 adverse events in either group were neutropenia (124 [51%] of 244 patients in the tucidinostat group vs three [2%] of 121 patients in the placebo group), thrombocytopenia (67 [27%] vs three [2%]), and leucopenia (46 [19%] vs three [2%]). Serious adverse events of any cause occurred in 51 (21%) of 244 patients in the tu…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30164-0

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Zhou, 2018, Chidamide reverses epidermal growth factor induced endocrine resistance in estrogen receptor-positive breast cancer, J Shenzhen Univ Sci Eng, 35, 339

Cited by

See all 289

Metadata

Authors
Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., Tong, Z., Cheng, Y., Pan, Y., Sun, Y., Wang, H., Ouyang, T., Gu, K., Feng, J., Wang, X., Wang, S., Liu, T., Gao, J., Cristofanilli, M., Ning, Z., & Lu, X.
Affiliations
  • Chinese PLA General Hospital (CN)
  • First Hospital of Jilin University (CN)
  • Fudan University (CN)
  • Third Affiliated Hospital of Harbin Medical University (CN)
  • Liaoning Cancer Hospital & Institute (CN)
  • Henan Cancer Hospital (CN)
  • Sun Yat-sen University (CN)
  • Hunan Cancer Hospital (CN)
  • Jiangsu Province Hospital (CN)
  • Tianjin Medical University Cancer Institute and Hospital (CN)
  • Jilin Province Tumor Hospital (CN)
  • Anhui Provincial Hospital (CN)
  • Jinan Central Hospital (CN)
  • Third Hospital of Nanchang (CN)
  • Peking University Cancer Hospital (CN)
  • First Affiliated Hospital of Anhui Medical University (CN)
  • Jiangsu Cancer Hospital (CN)
  • Zhejiang Cancer Hospital (CN)
  • Cangzhou Central Hospital (CN)
  • Shenzhen Chipscreen Biosciences Co. (CN)
Corresponding author
Jiang, Zefei
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2019-06
Volume
20
Issue
6
Pages
806-815
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2940712523
Cited by
270
References
30
Citations by year
2026: 19 · 2025: 36 · 2024: 52 · 2023: 38 · 2022: 46 · 2021: 38 · 2020: 34 · 2019: 7
FWCI
23.51
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Chinese National Major Project for New Drug Innovation (2015ZX09101005)
  • Shenzhen municipal science and technology project (JCYJ20120618162903087, JCYJ20160427185121156)
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Keywords
tucidinostat, chidamide, histone deacetylase inhibitors, exemestane, hormone receptor-positive breast cancer, HER2-negative breast cancer, postmenopausal women, advanced breast cancer, progression-free survival, endocrine therapy, visceral metastases, combination therapy, drug safety, tolerability, Chinese patients, overall survival
MeSH terms
Aminopyridines, Androstadienes, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Bone Neoplasms, Breast Neoplasms, Double-Blind Method, Female, Follow-Up Studies, Humans, Liver Neoplasms, Lung Neoplasms, Middle Aged, Neoplasm Recurrence, Local, Receptors, Estrogen, Receptors, Progesterone, Survival Rate, Salvage Therapy, Treatment Outcome, Postmenopause, Erb-b2 Receptor Tyrosine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30164-0
The paper
Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., Tong, Z., Cheng, Y., Pan, Y., Sun, Y., Wang, H., Ouyang, T., Gu, K., Feng, J., Wang, X., . . . Lu, X. (2019). Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30164-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.